Sarepta Therapeutics (SRPT), Selecta Biosciences (SELB) Announce Research License & Option Agreement for ImmTOR Immune Tolerance Platform in Neuromuscular Diseases Jun 18, 2020 08:32AM
Sarepta Therapeutics and Selecta Biosciences Enter Into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases Jun 18, 2020 08:30AM
Sarepta Therapeutics and Selecta Biosciences Enter into Research License and Option Agreement for Selecta’s ImmTOR Immune Tolerance Platform in Neuromuscular Diseases Jun 18, 2020 08:30AM
Selecta Biosciences Expands Potential for ImmTOR™ Platform and Streamlined Structure Under Leadership of New CEO, Carsten Brunn, Ph.D. Jan 3, 2019 04:11PM
Seer Debuts with Proprietary Proteomics Platform to Enable Early Detection of Cancer and Neurological Diseases Dec 17, 2018 07:00AM
View Older Stories

Dec 3, 2018 08:00AM Selecta Biosciences Announces New Employment Inducement Grants
Nov 8, 2018 08:00AM Selecta Biosciences Announces Third Quarter 2018 Financial Results and Provides Corporate Update
Nov 6, 2018 08:00AM Selecta Biosciences to Present at the Stifel Healthcare Conference 2018
Nov 1, 2018 08:00AM Selecta Biosciences to Report Third Quarter 2018 Financial Results and Update on SEL-212 Development Strategy, including Planned Head-to-Head Study versus Krystexxa
Oct 23, 2018 07:10AM Selecta Biosciences (SELB) Presents New Interim Data from Phase 2 Trial of SEL-212
Oct 23, 2018 07:05AM Selecta Biosciences Presents New Interim Data from Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at ACR 2018
Oct 16, 2018 08:00AM Selecta Biosciences to Present New Five Monthly Dose Phase 2 Data for SEL-212 in Chronic, Severe Gout at Upcoming 2018 ACR Annual Meeting
Oct 5, 2018 10:01AM Co-administration of AAV Vectors with SVP-Rapamycin Enables Vector Re-administration in Pre-clinical Gene Therapy Study Published in Nature Communications by Généthon and Selecta Biosciences
Sep 27, 2018 07:32AM Selecta Biosciences (SELB) Names Carsten Brunn Ph.D. as President and CEO
Sep 27, 2018 07:30AM Selecta Biosciences Appoints Carsten Brunn, Ph.D. as President and Chief Executive Officer
Sep 25, 2018 08:00AM Selecta Biosciences to Present at the Cantor Fitzgerald Global Healthcare Conference on October 02, 2018
Sep 20, 2018 08:00AM Selecta Biosciences to Present at the Jefferies Gene Therapy Summit on September 27, 2018
Sep 10, 2018 08:00AM Selecta Biosciences to Present at the Janney Healthcare Conference on September 17, 2018
Aug 31, 2018 08:00AM Selecta Biosciences Announces Presentation at the 20th Asia Pacific League of Associations for Rheumatology Congress (APLAR)
Aug 8, 2018 08:00AM Selecta Biosciences Announces Second Quarter 2018 Financial Results and Provides Corporate Update
Aug 2, 2018 08:00AM Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2018
Aug 1, 2018 08:00AM Selecta Biosciences Announces Date of Second Quarter 2018 Financial Results Conference Call
Jun 15, 2018 05:38AM Selecta Biosciences (SELB) Highlights Data from Ongoing Phase 2 Trial of SEL-212 at EULAR 2018
Jun 15, 2018 05:30AM Selecta Biosciences Presents Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
Jun 8, 2018 08:00AM Selecta Biosciences to Present Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at EULAR 2018
May 30, 2018 08:00AM Selecta Biosciences to Present at the Jefferies Global Healthcare Conference on June 06, 2018
May 9, 2018 08:00AM Selecta Biosciences Announces First Quarter 2018 Financial Results and Provides Corporate Update
May 2, 2018 08:00AM Selecta Biosciences Announces Date of First Quarter 2018 Financial Results Conference Call
May 1, 2018 08:00AM Selecta Biosciences to Present at Upcoming Investor Conferences
Apr 10, 2018 08:07AM Selecta Biosciences (SELB) Announces Positive New Data from Ongoing Phase 2 Trial of SEL-212 for Chronic Severe Gout Treatment
Apr 10, 2018 08:00AM Selecta Biosciences Presents Positive New Data from Ongoing Phase 2 Trial of SEL-212, in Development for Chronic Severe Gout, at PANLAR 2018 Congress
Apr 3, 2018 08:00AM Selecta Biosciences to Present Updated Clinical Phase 2 Data of Lead Candidate SEL-212 at the Pan American League of Associations for Rheumatology (PANLAR) Congress on April 10, 2018
Mar 20, 2018 04:01PM Selecta Biosciences to Present at the Needham Healthcare Conference on March 27, 2018
Mar 15, 2018 08:00AM Selecta Biosciences Announces Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update
Mar 12, 2018 08:09AM Selecta Biosciences (SELB) Doses First Patient in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination
Mar 12, 2018 08:00AM Selecta Biosciences Announces First Patient Dosed in Phase 1 Trial of SVP-Rapamycin and LMB-100 Combination Therapy in Mesothelioma
Mar 8, 2018 08:00AM Selecta Biosciences to Report Fourth Quarter and Year End 2017 Financial Results on Thursday, March 15, 2018
Jan 9, 2018 08:00AM Publication Authored by Researchers at Selecta Biosciences and the National Cancer Institute in Proceedings of the National Academy of Sciences (PNAS) Discusses Restoration of Anti-Tumor Activity of R
Jan 2, 2018 08:06AM Selecta Biosciences (SELB) Reports CEO's Intent to Retire and Transition Plan
Jan 2, 2018 08:06AM Selecta Biosciences (SELB) Announces FDA Acceptance of IND for LMB-100 and SVP-Rapamycin Combination Therapy
Jan 2, 2018 08:05AM Selecta Biosciences Announces FDA Acceptance of Investigational New Drug Application for LMB-100 and SVP-Rapamycin Combination Therapy
Jan 2, 2018 08:00AM Selecta Biosciences Announces CEO’s Intent to Retire and Transition Plan
Nov 13, 2017 08:00AM Selecta Biosciences to Webcast Investor Conference Presentations This Week
Nov 7, 2017 07:30AM Selecta Biosciences Announces Third Quarter 2017 Financial Results and Provides Corporate Update
Oct 31, 2017 08:00AM Selecta Biosciences to Report Third Quarter 2017 Financial Results and Updated Phase 2 Data for SEL-212 on Tuesday, November 7, 2017
Oct 26, 2017 08:00AM Selecta Biosciences Announces Important Additions to Senior Leadership Team
Oct 5, 2017 08:00AM Selecta Biosciences Announces Upcoming Clinical and Scientific Presentations
Sep 19, 2017 08:00AM Selecta Biosciences to Participate in Upcoming Investor Conferences
Aug 11, 2017 07:00AM Selecta Biosciences Announces Second Quarter 2017 Financial Results and Provides Corporate Update
Aug 4, 2017 08:00AM Selecta Biosciences to Report Second Quarter 2017 Financial Results on Friday, August 11, 2017
Aug 2, 2017 08:00AM Selecta Biosciences to Present at the Canaccord Growth Conference on August 9, 2017
Jun 26, 2017 08:09AM Selecta Biosciences (SELB) Reports $50M Private Placement of Common Stock
Jun 26, 2017 08:00AM Selecta Biosciences Announces $50 Million Private Placement
Jun 19, 2017 08:14AM Selecta Biosciences (SELB) Appoints Patrick Zenner to Board
Jun 19, 2017 08:00AM Selecta Biosciences Announces Addition of Patrick J. Zenner to Board of Directors
View Older Stories